Overview
In order to assessment the safety and efficacy of debulking atherectomy versus stent angioplasty for limb ischaemia of diabetic lower limb atherosclerosis-occlusive disease, we intend to conduct a prospective, multicenter, randomized controlled, non-inferiority trial. The main surgical methods included stent angioplasty group (Nickel-titanium self-expanding bare stent) and debulking atherectomy group (Excimer laser atherectomy combined with drug-coated balloon angioplasty). The sample size was 244 patients, and the patients were followed up at 30 days, 180 days, and 365 days after operation.
Eligibility
Inclusion Criteria:
- Age 40-80 years old
- Rutherford grade 2 to 5
- Patients clinically diagnosed with arteriosclerosis obliterans of lower extremity (stenosis of lower extremity arteries greater than 70% or occlusion) and complicated with diabetes
- The target vessel diameter ≥4mm
- The total target length of the lesion is 30-210mm
- The subject is able and willing to comply with all requirements, including 12-month follow-up and evaluation, voluntary participation and informed consen
- Patients with ipsilateral iliac artery inflow tract patency (stenosis ≤50%) or ipsilateral iliac artery inflow tract lesions and successful management (residual stenosis < 30% after treatment, no severe (≥ grade D) flow-limiting dissection , no thrombosis, embolism or other serious adverse events)
- Patients with at least one infrapopliteal artery for patency of the affected lateral foot before or after intraoperative treatment (stenosis ≤50%)
Exclusion Criteria:
- Patients with vasculitis or Berger disease
- Patients with contraindications to antiplatelet, anticoagulant and thrombolytic drugs
- Patients who are allergic to contrast agents and nickel titanium materials
- Patients with severe coagulation dysfunction or severe infection that is not under control and should not undergo surgery
- Severe renal dysfunction (creatinine > 221umol/L)
- Patients who received local or systemic thrombolytic therapy within 48 hours before surgery
- Patients who had acute myocardial infarction within 30 days before surgery
- Patients who had undergone major surgical procedures (heart, abdominal, or peripheral vascular open surgery) within 30 days before surgery
- Patients who had a stroke within 6 months before surgery
- Patients whose target arteries had received endovascular surgery within 14 days prior to surgery and patients who had other elective surgery plans during the study period
- Patients with end-stage renal disease
- Patients with previous major amputation of the target limb or restenosis after stent or bypass surgery for the target lesion
- Patients with perforation, dissection, or other vascular injury requiring stenting or surgical operation in the approach or target vessel prior to enrollment
- Patients with a life expectancy of < 12 months
- A woman who is pregnant or breastfeeding
- Patients who are participating in clinical trials of other drugs or devices that do not meet trial endpoints
- Patients considered unsuitable for this trial by the investigators Exclusion criteria for angiography
- Patients with severe calcification of the target lesions
- Patients with aneurysms in the target vessels
- Patients with acute or subacute thrombus in the target vessel
- Patients with artificial vessels placed in the limb on the same side of the target vessel